Cargando…

Treatment of Indolent and Advanced Systemic Mastocytosis

Management of Indolent and Smoldering SM is focused on preventing anaphylactic reactions and identifying and avoiding symptom triggers. Skin and gastrointestinal symptoms are managed with H1- and H2-antihistamines. When skin symptoms are not adequately controlled, leukotriene antagonists and oral ps...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buonomo, Alessandro, Nucera, Eleonora, Criscuolo, Marianna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Università Cattolica del Sacro Cuore 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9084172/ https://www.ncbi.nlm.nih.gov/pubmed/35615325 http://dx.doi.org/10.4084/MJHID.2022.040

Ejemplares similares

Efficacy of Omalizumab in Indolent Systemic Mastocytosis
por: Slapnicar, Calum, et al.
Publicado: (2019)

Mastocytosis: One Word for Different Diseases
por: Criscuolo, Marianna, et al.
Publicado: (2018)

Indolent systemic mastocytosis in a patient with ileocolitis
por: Chrysakopoulos, Georgios, et al.
Publicado: (2014)

Delayed Diagnosis of Adult Indolent Systemic Mastocytosis
por: Mikkelsen, Carsten Sauer, et al.
Publicado: (2014)

Indolent systemic mastocytosis mimicking Crohn’s disease
por: Hadjivasilis, Alexandros, et al.
Publicado: (2019)

DNA methylation profile in patients with indolent systemic mastocytosis
por: Górska, Aleksandra, et al.
Publicado: (2021)

Indolent Systemic Mastocytosis Manifesting as Protracted Anaphylactic Shock
por: Chatterjee, Manidipam, et al.
Publicado: (2018)

Primary cicatricial alopecia associated with systemic indolent mastocytosis
por: Prasad, Sonya, et al.
Publicado: (2020)

Diagnosis of indolent systemic mastocytosis in a patient with “seborrheic keratosis”
por: Moshref Razavi, Habib, et al.
Publicado: (2022)

Indolent systemic mastocytosis associated with light chain deposition disease
por: Sasaki, Kotaro, et al.
Publicado: (2012)

Venom immunotherapy in indolent systemic mastocytosis with high serum tryptase level
por: Selcuk, Ali, et al.
Publicado: (2021)

Novel approaches to treating advanced systemic mastocytosis
por: Gilreath, JA, et al.
Publicado: (2019)

Clinical potential of midostaurin in advanced systemic mastocytosis
por: Chandesris, Marie Olivia, et al.
Publicado: (2017)

Genome-Wide DNA Methylation and Gene Expression in Patients with Indolent Systemic Mastocytosis
por: Górska, Aleksandra, et al.
Publicado: (2023)

Recent advances in diagnosis and therapy in systemic mastocytosis
por: Lee, Hyun Jung
Publicado: (2023)

Pancreatic neuroendocrine tumor presenting in indolent systemic mastocytosis: A case report
por: Sacco, Keith, et al.
Publicado: (2020)

Target Therapies for Systemic Mastocytosis: An Update
por: Sciumè, Mariarita, et al.
Publicado: (2022)

Development of symptom-focused outcome measures for advanced and indolent systemic mastocytosis: the AdvSM-SAF and ISM-SAF(©)
por: Taylor, Fiona, et al.
Publicado: (2021)

Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression
por: Verstovsek, Srdan
Publicado: (2013)

Serum Tryptase Monitoring in Indolent Systemic Mastocytosis: Association with Disease Features and Patient Outcome
por: Matito, Almudena, et al.
Publicado: (2013)

Treatment of Advanced Systemic Mastocytosis with Midostaurin: Practical Guidance for Optimal Therapy and Management
por: Papayannidis, Cristina, et al.
Publicado: (2022)

Systemic Mastocytosis: Molecular Landscape and Implications for Treatment
por: Monaldi, Cecilia, et al.
Publicado: (2021)

The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis
por: Mannelli, Francesco, et al.
Publicado: (2023)

Preclinical human models and emerging therapeutics for advanced systemic mastocytosis
por: Arock, Michel, et al.
Publicado: (2018)

Delayed Diagnosis of Indolent Systemic Mastocytosis as the Cause of Unexplained Skin Rash: A Case Report
por: Alshurafa, Awni, et al.
Publicado: (2023)

Precision Medicine in Systemic Mastocytosis
por: Nicolosi, Maura, et al.
Publicado: (2021)

FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis
por: Kasamon, Yvette L., et al.
Publicado: (2018)

Systemic Mastocytosis: Multidisciplinary Approach
por: Zanotti, Roberta, et al.
Publicado: (2021)

Recent advances in the understanding and therapeutic management of mastocytosis
por: Rossignol, Julien, et al.
Publicado: (2019)

Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors
por: Shomali, William, et al.
Publicado: (2021)

Indolent systemic mastocytosis and aleukemic mast cell leukemia: Subtle diagnostic differences with distinct management approaches
por: Paiva, Marcelo L., et al.
Publicado: (2023)

New Insights into the Pathogenesis of Systemic Mastocytosis
por: Li, Zhixiong
Publicado: (2021)

Recent Advances in the Molecular Biology of Systemic Mastocytosis: Implications for Diagnosis, Prognosis, and Therapy
por: Martelli, Margherita, et al.
Publicado: (2020)

The Role of Avapritinib for the Treatment of Systemic Mastocytosis
por: Sumbly, Vikram, et al.
Publicado: (2021)

Systemic Mastocytosis: Radiological Point of View
por: Leone, Antonio, et al.
Publicado: (2021)

Melanoma and Mastocytosis
por: Vojvodic, Aleksandra, et al.
Publicado: (2019)

Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis
por: Reiter, Andreas, et al.
Publicado: (2022)

Current Concepts on Diagnosis and Treatment of Mastocytosis
por: Magliacane, D., et al.
Publicado: (2014)

Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis
por: Reiter, Andreas, et al.
Publicado: (2022)

Anaphylaxis after horsefly sting: a strange case of wasp-horsefly syndrome
por: Buonomo, Alessandro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1onsrd73qca1iopfsl74anietv